Hostname: page-component-7dd5485656-hw7sx Total loading time: 0 Render date: 2025-10-30T19:30:06.025Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparative Killing Kinetics of Methicillin-Resistant Staphylococcus aureus by Bacitracin or Mupirocin

Published online by Cambridge University Press:  02 January 2015

Edward K. Chapnick ,
Jeremy D. Gradon ,
Barry Kreiswirth ,
Larry I. Lutwick ,
Benjamin C. Schaffer ,
Thomas D. Schiano  and
Michael H. Levi
Get access Rights & Permissions [Opens in a new window]

Abstract

The in vitro activities of bacitracin and mupirocin were compared for seven different strains of methicillin-resistant Staphylococcus aureus. Six of seven strains showed bacitracin minimum inhibitory concentrations (MICs) of 0.5 to 1.0 units/mL, and all seven had mupirocin MICs of 0.5 to 2 μg/mL. Time-kill studies revealed 2.6- to 4.5-log reduction in 24 hours with strains susceptible to bacitracin (4 units/mL) and 0 to 2.2 reduction with mupirocin (16 μg/mL). Bacitracin should be considered further for in vivo studies because of enhanced bacteriocidal effect and lower cost.

Information

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 17 , Issue 3 , March 1996 , pp. 178 - 180
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Brumfit, W, Hamilton-Miller, J. Methicillin-resistant Staphylococcus aureus . N Engl J Med 1989;320:1188–1196.CrossRefGoogle Scholar
2. Bryan, CS, Wilson, RS, Meade, P, Sill, LG. Topical antibiotic ointments for staphylococcal nasal carriers: survey of current practices and comparison of bacitracin and vancomycin ointments. Infect Control 1980;1:153–156.CrossRefGoogle ScholarPubMed
3. Bradley, SF, Ramsey, MA, Morton, TM, Kauffman, CA. Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 1995;16:354–358.Google Scholar
4. Frank, U, Lenz, W, Damrath, E, Kappstein, I, Daschner, FD. Nasal carriage of Staphylococcus aureus treated with topical mupirocin (pseudomonic acid) in a children's hospital. J Hosp Infect 1989;13:117–120.CrossRefGoogle ScholarPubMed
5. Kreiswirth, BN, Kornbluth, J, Arbeit, RD, et al. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus . Science 1992;259:227–230.Google Scholar
6. Muder, RR, Brennen, C, Wagener, MM, et al. Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med 1991;114:107–112.CrossRefGoogle ScholarPubMed
7. McAnally, TP, Lewis, MR, Brown, DR. The effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus . Antimicrob Agents Chemother 1984;25:422–426.CrossRefGoogle ScholarPubMed
8. Casewell, MW, Hill, RLR. In-vitro activity of mupirocin (pseudomonic acid) against clinical isolates of Staphylococcus aureus . J Antimicrob Chemother 1985;15:523–531.Google Scholar
9. Kauffman, CA, Terpenning, MS, He, X, Zarins, LT, Ramsay, MA, Jorgenson, KA. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long term care facility with the use of mupirocin ointment. Am J Med 1993;94:371–378.Google Scholar
10. Reagan, DR, Doebbeling, DN, Pfaller, MA, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101–106.Google Scholar